Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients
NCT ID: NCT00919607
Last Updated: 2010-03-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
31 participants
INTERVENTIONAL
2009-06-30
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients
NCT00882518
Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression
NCT01256177
Seroquel XR in Adults With Schizophrenia
NCT00852631
Fast Titration in the Treatment of Schizophrenia, Taiwan
NCT00304473
The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics
NCT02142556
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
quetiapine fumarate extended-release 300mg,administered once-daily Day1\~5
quetiapine fumarate extended-release
300mg,oral,single dose
2
quetiapine fumarate extended-release 300mg/Day1,600mg/Day2\~6,administered once-daily
quetiapine fumarate extended-release
300mg,oral,single dose
3
quetiapine fumarate extended-release 300mg/Day1,600mg/Day2,800mg/Day3\~7,administered once-daily
quetiapine fumarate extended-release
200mg,oral,single dose
quetiapine fumarate extended-release
300mg,oral,single dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
quetiapine fumarate extended-release
200mg,oral,single dose
quetiapine fumarate extended-release
300mg,oral,single dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Schizophrenia diagnosis
* Body Mass Index (BMI) 20-27 kg/m2 (inclusive)
* Provision of written informed consent before initiation of any study
Exclusion Criteria
* History of seizure disorder
* History of episodic,idiopathic orthostatic hypotension
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tianmei Si
Role: PRINCIPAL_INVESTIGATOR
Peking University Institute of Mental Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1444C00007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.